6.32
Neogenomics Inc 주식(NEO)의 최신 뉴스
What are the latest earnings results for NeoGenomics Inc.Strong return on assets - jammulinksnews.com
How many analysts rate NeoGenomics Inc. as a “Buy”Maximize gains with professional stock picks - jammulinksnews.com
NeoGenomics (NEO): A Buy-the-Dip Opportunity in Oncology Diagnostics or a Risky Bet? - AInvest
How volatile is NeoGenomics Inc. stock compared to the marketBuild wealth faster with consistent growth stocks - jammulinksnews.com
NeoGenomics (NEO) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What are the technical indicators suggesting about NeoGenomics Inc.Maximize your portfolio’s growth potential - jammulinksnews.com
What institutional investors are buying NeoGenomics Inc. stockFastest return on investment - jammulinksnews.com
What is the risk reward ratio of investing in NeoGenomics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
When is NeoGenomics Inc. stock expected to show significant growthDiscover hidden gems in the stock market - jammulinksnews.com
How strong is NeoGenomics Inc. company’s balance sheetGet timely alerts on market movers - jammulinksnews.com
What is the dividend policy of NeoGenomics Inc. stockFree Buy/Sell Signal Notifications - jammulinksnews.com
What is NeoGenomics Inc. company’s growth strategyFree Consultation - jammulinksnews.com
Is NeoGenomics Inc. stock overvalued or undervaluedBuild a winning portfolio with smart picks - jammulinksnews.com
What drives NeoGenomics Inc. stock priceFree Predictions - PrintWeekIndia
Is NeoGenomics Inc. a good long term investmentRapid profit acceleration - PrintWeekIndia
NeoGenomics Inc. Stock Analysis and ForecastTremendous growth potential - PrintWeekIndia
Will NeoGenomics Inc. stock benefit from AI tech trendsRapid wealth multiplication - jammulinksnews.com
What analysts say about NeoGenomics Inc. stockExceptional trading performance - PrintWeekIndia
NeoGenomics (NEO) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy - Nature
Bank of America Securities Sticks to Their Hold Rating for NeoGenomics (NEO) - The Globe and Mail
Neogenomics Shares Plunge 7.14% Amid Earnings Woes - AInvest
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
Pathological Examination Market Gaining Momentum in Cancer - openPR.com
NeoGenomics (NASDAQ:NEO investor five-year losses grow to 81% as the stock sheds US$71m this past week - simplywall.st
Why NeoGenomics Inc. stock attracts strong analyst attention200 Percent Profit Outlook - beatles.ru
Q1 Earnings Highlights: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Testing & Diagnostics Services Stocks - Yahoo Finance
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO - ACCESS Newswire
자본화:
|
볼륨(24시간):